Skip to main navigation Skip to search Skip to main content

Management Lessons from Clinical Trials of Kidney Disease in Systemic Lupus Erythematosus

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Clinically significant lupus nephritis occurs in about 40% of the overall systemic lupus erythematosus population. Despite aggressive therapy with anti-inflammatory and immunosuppressive drugs, chronic kidney damage and kidney failure are common in lupus nephritis patients. Also, standard-of-care treatment regimens are associated with significant toxicity and patient morbidity. To address this problem, a number of prospective, controlled, randomized clinical trials of potential new therapies have been undertaken recently in lupus nephritis. Unfortunately, none of these trials succeeded in demonstrating better renal outcomes or less toxicity than the standard-of-care approaches. Despite these failures, all of the trials provide important insights into the clinical behavior of lupus nephritis, which can be translated into more effective management strategies. This chapter examines lessons from lupus nephritis clinical trials and uses these lessons to build a new framework for future trials of new therapeutics.

Original languageEnglish
Title of host publicationSystemic Lupus Erythematosus
Subtitle of host publicationBasic, Applied and Clinical Aspects
PublisherElsevier Inc.
Pages559-566
Number of pages8
ISBN (Electronic)9780128020098
ISBN (Print)9780128019177
DOIs
StatePublished - Jan 1 2016

Keywords

  • Autoimmunity
  • Clinical trial
  • Glomerulonephritis
  • Inflammation
  • Kidney biopsy
  • Renal response

Fingerprint

Dive into the research topics of 'Management Lessons from Clinical Trials of Kidney Disease in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this